Key result
Intensive blood pressure control reduced major adverse cardiovascular events by 20% (RR 0.80) compared to standard control, yielding an absolute risk reduction of 1.5%.
Why the study?
While the benefits of reducing blood pressure are established, the optimal blood pressure level to maintain remains debatable.
Does intensive blood pressure control reduce major adverse cardiovascular events in patients with hypertension compared to standard blood pressure control?
Meta-Analysis (n=37,249)
Does intensive blood pressure control reduce major adverse cardiovascular events in patients with hypertension compared to standard blood pressure control?
Intensive blood pressure control significantly reduces the risk of major adverse cardiovascular events but is associated with an increased risk of adverse events such as hypotension and acute kidney injury.
Answers are grounded in this paper and cite their sources.
Supports intensive targets with monitoring for hypotension and AKI; confirms consistent RCT evidence for lower BP goals.
Hypertension is one of the most frequent non-inherited risks to health that contributes to cardiovascular disease. Whereas the effects of reducing blood pressure are clear-cut, it is debatable what the optimal blood pressure level should be maintained. The objective of this systematic review and meta-analysis was to compare intensive blood pressure control with standard blood pressure control regarding cardiovascular outcomes, specifically focusing on major adverse cardiovascular events (MACE). We searched electronic databases comprehensively (PubMed, Embase, and Cochrane Library) from inception up to March 2025 to find randomized controlled trials comparing intensive control of systolic blood pressure with standard control. The primary outcome was MACE, a composite measure including all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, heart failure, and adverse events. Meta-analysis was performed using random effects to measure risk ratios (RRs) and 95% confidence intervals (CIs). Our analysis incorporated 37,249 subjects from 12 randomized controlled trials. Intensive blood pressure control significantly decreased the odds of MACE (RR: 0.80, 95% CI: 0.73-0.88) compared to standard management. Notable reductions were also observed in cardiovascular mortality (RR: 0.78, 95% CI: 0.67-0.90), stroke (RR: 0.78, 95% CI: 0.68-0.90), and heart failure (RR: 0.73, 95% CI: 0.61-0.88). However, intensive management was associated with higher risks of hypotension, syncope, electrolyte imbalance, and acute kidney injury. Overall, our results indicate that achieving lower blood pressure targets yields significant cardiovascular benefits, particularly in reducing MACE, cardiovascular mortality, stroke, and heart failure. However, these advantages must be weighed against the increased risk of adverse events. Treatment decisions should be individualized based on patient characteristics, risk factors, and preferences. Additionally, moderate heterogeneity was noted across studies, and the risk of bias was assessed, revealing good methodological quality overall.
No takes yet. Share an insight, caveat, or question.
Rizwanullah et al. (2025) conducted a meta-analysis in Hypertension (n=37,249). Intensive blood pressure control vs. Standard blood pressure control (Target 140-150/90 mmHg) was evaluated on Major adverse cardiovascular events (MACE) composite including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (RR 0.80, 95% CI 0.73-0.88, p=<0.001). Intensive blood pressure control reduced major adverse cardiovascular events by 20% (RR 0.80) compared to standard control, yielding an absolute risk reduction of 1.5%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: